Alberto Corsini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7139533/publications.pdf

Version: 2024-02-01

198	15,191	46918 47	21474 114
papers	citations	h-index	g-index

203	203	203	16616
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	1.0	4,871
2	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	1.0	1,024
3	New insights into the pharmacodynamic and pharmacokinetic properties of statins. , 1999, 84, 413-428.		674
4	Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. Circulation, 2004, 109, III-50-III-57.	1.6	469
5	Risk for Myopathy With Statin Therapy in High-Risk Patients. Archives of Internal Medicine, 2003, 163, 553.	4.3	404
6	Non-lipid-related effects of statins. Annals of Medicine, 2000, 32, 164-176.	1.5	300
7	Adverse effects of statin therapy: perception vs. the evidence â€“ focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	1.0	262
8	Dysfunction of the Cholesterol Biosynthetic Pathway in Huntington's Disease. Journal of Neuroscience, 2005, 25, 9932-9939.	1.7	236
9	Pharmacology of competitive inhibitors of HMg-CoA reductase. Pharmacological Research, 1995, 31, 9-27.	3.1	225
10	Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis, 1993, 101, 117-125.	0.4	212
11	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012, 220, 381-386.	0.4	212
12	Pharmacology of Dipeptidyl Peptidase-4 Inhibitors. Drugs, 2011, 71, 1441-1467.	4.9	196
13	Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis, 1998, 137, S101-S109.	0.4	193
14	PCSK9 induces a pro-inflammatory response in macrophages. Scientific Reports, 2018, 8, 2267.	1.6	166
15	Drug attrition during pre-clinical and clinical development: Understanding and managing drug-induced cardiotoxicity. , 2013, 138, 470-484.		161
16	PPARÎ± inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. Journal of Clinical Investigation, 2005, 115, 3228-3238.	3.9	145
17	Role of polymorphonuclear neutrophils in atherosclerosis: Current state and future perspectives. Atherosclerosis, 2010, 210, 1-13.	0.4	141
18	Drugâ€Induced Liver Injury: The Role of Drug Metabolism and Transport. Journal of Clinical Pharmacology, 2013, 53, 463-474.	1.0	126

#	Article	IF	Citations
19	Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties. Drugs, 2013, 73, 1681-1709.	4.9	118
20	Statin drug interactions and related adverse reactions: an update. Expert Opinion on Drug Safety, 2018, 17, 25-37.	1.0	114
21	The role of mitochondria in statinâ€induced myopathy. European Journal of Clinical Investigation, 2015, 45, 745-754.	1.7	110
22	Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017, 256, 1-6.	0.4	98
23	Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacological Research, 2018, 134, 51-60.	3.1	98
24	Virtual Screening Approach for the Identification of New Rac1 Inhibitors. Journal of Medicinal Chemistry, 2009, 52, 4087-4090.	2.9	96
25	Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. Journal of Biological Chemistry, 2016, 291, 3508-3519.	1.6	93
26	Pharmacokinetic Interactions Between Statins and Fibrates. American Journal of Cardiology, 2005, 96, 44-49.	0.7	87
27	Statin drug interactions and related adverse reactions. Expert Opinion on Drug Safety, 2012, 11, 933-946.	1.0	87
28	Safety considerations for statins. Current Opinion in Lipidology, 2002, 13, 637-644.	1.2	85
29	The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practice. Atherosclerosis Supplements, 2014, 15, 1-15.	1.2	83
30	Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacological Research, 2018, 135, 60-79.	3.1	81
31	Non-Lipid-Related Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Cardiology, 1996, 87, 458-468.	0.6	80
32	PCSK9 inhibition and inflammation: A narrative review. Atherosclerosis, 2019, 288, 146-155.	0.4	80
33	Direct Effects of Statins on the Vascular Wall. Journal of Cardiovascular Pharmacology, 1998, 31, 773-778.	0.8	80
34	PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis, 2016, 253, 214-224.	0.4	78
35	Pharmacokinetics interactions of monoclonal antibodies. Pharmacological Research, 2016, 111, 592-599.	3.1	78
36	Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacological Research, 1991, 23, 173-180.	3.1	75

#	Article	IF	Citations
37	The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovascular Drugs and Therapy, 2003, 17, 265-285.	1.3	75
38	Pharmacological interactions of statins. Atherosclerosis Supplements, 2002, 3, 35-40.	1.2	72
39	Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacological Research, 2007, 55, 441-449.	3.1	72
40	Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. Journal of Pharmacology and Experimental Therapeutics, 1997, 281, 1144-53.	1.3	69
41	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels â€“ experimental and clinical approaches with lipid-lowering agents. European Journal of Preventive Cardiology, 2019, 26, 930-949.	0.8	64
42	Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2021, 191, 1385-1397.	1.9	62
43	Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicology Letters, 1992, 64-65, 1-15.	0.4	60
44	Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. American Journal of Cardiology, 1995, 76, 21A-28A.	0.7	59
45	Phytosterols, Cholesterol Control, and Cardiovascular Disease. Nutrients, 2021, 13, 2810.	1.7	58
46	Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovascular Research, 2023, 118, 3288-3304.	1.8	57
47	Clinical approach to the inflammatory etiology of cardiovascular diseases. Pharmacological Research, 2020, 159, 104916.	3.1	56
48	Drugâ€“drug interactions with statins: will pitavastatin overcome the statinsâ€™ Achillesâ€™ heel?. Current Medical Research and Opinion, 2011, 27, 1551-1562.	0.9	55
49	Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet, The, 1996, 348, 1584.	6.3	53
50	Everolimus Inhibits Monocyte/Macrophage Migration in Vitro and Their Accumulation in Carotid Lesions of Cholesterol-Fed Rabbits. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 419-425.	1.3	52
51	Severe hypercholesterolaemia: unusual inheritance in an Italian pedigree. European Journal of Clinical Investigation, 1995, 25, 322-331.	1.7	48
52	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis, 2010, 210, 78-87.	0.4	48
53	Effect of the New Calcium Antagonist Lercanidipine and Its Enantiomers on the Migration and Proliferation of Arterial Myocytes. Journal of Cardiovascular Pharmacology, 1996, 28, 687-694.	0.8	47
54	Effects of calcium antagonists on lipids and atherosclerosis. American Journal of Cardiology, 1989, 64, I129-I134.	0.7	45

#	Article	IF	Citations
55	Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atherosclerosis Supplements, 2015, 16, 1-27.	1.2	45
56	Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Translational Research, 2016, 173, 19-29.	2.2	45
57	Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacological Research, 2018, 128, 29-41.	3.1	45
58	Reviews: Fluvastatin: Effects Beyond Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics, 2000, 5, 161-175.	1.0	44
59	PPAR-Î± agonists are still on the rise: an update on clinical and experimental findings. Expert Opinion on Investigational Drugs, 2017, 26, 593-602.	1.9	44
60	Appropriateness of statin prescription in the elderly. European Journal of Internal Medicine, 2018, 50, 33-40.	1.0	43
61	Recombinant LCAT (Lecithin:Cholesterol Acyltransferase) Rescues Defective HDL (High-Density) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Thrombosis, and Vascular Biology, 2019, 39, 915-924.	1.1	41
62	Lipid Lowering Drugs: Present Status and Future Developments. Current Atherosclerosis Reports, 2021, 23, 17.	2.0	41
63	Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care, 2000, 23 Suppl 2, B72-8.	4.3	41
64	Effects of 26-Aminocholesterol, 27-Hydroxycholesterol, and 25-Hydroxycholesterol on Proliferation and Cholesterol Homeostasis in Arterial Myocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 420-428.	1.1	39
65	EFFECT OF THE NEW HMG-CoA REDUCTASE INHIBITOR CERIVASTATIN (BAY W 6228) ON MIGRATION, PROLIFERATION AND CHOLESTEROL SYNTHESIS IN ARTERIAL MYOCYTES. Pharmacological Research, 1996, 33, 55-61.	3.1	39
66	Simvastatin Reduces MMP1 Expression in Human Smooth Muscle Cells Cultured on Polymerized Collagen by Inhibiting Rac1 Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1043-1049.	1.1	39
67	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis, 2019, 285, 40-48.	0.4	39
68	Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation. British Journal of Pharmacology, 2003, 138, 811-818.	2.7	37
69	ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Expert Opinion on Pharmacotherapy, 2019, 20, 791-803.	0.9	37
70	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. Atherosclerosis, 2011, 214, 331-337.	0.4	36
71	Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. European Journal of Preventive Cardiology, 2019, 26, 578-588.	0.8	36
72	Clinically relevant pleiotropic effects of statins: drug properties or effects of profound cholesterol reduction?. Nutrition, Metabolism and Cardiovascular Diseases, 2001, 11, 328-43.	1.1	35

#	Article	IF	Citations
73	Calcium Antagonists and Low Density Lipoprotein Receptors. Annals of the New York Academy of Sciences, 1988, 522, 390-398.	1.8	34
74	Do structural differences in statins correlate with clinical efficacy?. Current Opinion in Lipidology, 2010, 21, 298-304.	1.2	31
75	2-Amino-3-(phenylsulfanyl)norbornane-2-carboxylate: An Appealing Scaffold for the Design of Rac1â€“Tiam1 Proteinâ€“Protein Interaction Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 2953-2962.	2.9	31
76	Depression and cardiovascular riskâ€”association among Beck Depression Inventory, PCSK9 levels and insulin resistance. Cardiovascular Diabetology, 2020, 19, 187.	2.7	31
77	Clinical Pharmacology of Statins: an Update. Current Atherosclerosis Reports, 2020, 22, 26.	2.0	31
78	Role of Small GTPase Protein Rac1 in Cardiovascular Diseases. Journal of Cardiovascular Pharmacology, 2013, 62, 425-435.	0.8	30
79	Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia.. Journal of Clinical Investigation, 1986, 78, 940-946.	3.9	30
80	Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. Atherosclerosis, 1992, 93, 95-103.	0.4	29
81	Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers, 2005, 10, 219-237.	0.9	29
82	Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice. Pharmaceutics, 2022, 14, 1120.	2.0	29
83	Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 469-474.	1.0	28
84	Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?. Annals of Medicine, 2018, 50, 461-484.	1.5	28
85	Chemotactic effect of prorenin on human aortic smooth muscle cells: a novel function of the (pro)renin receptor. Cardiovascular Research, 2012, 95, 366-374.	1.8	27
86	Hypolipidemic therapy for the metabolic syndrome. Pharmacological Research, 2006, 53, 492-500.	3.1	26
87	Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Current Opinion in Lipidology, 2006, 17, 495-501.	1.2	26
88	3-Aryl-N-aminoylsulfonylphenyl-1H-pyrazole-5-carboxamides: a new class of selective Rac inhibitors. MedChemComm, 2013, 4, 537.	3.5	26
89	Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9. American Journal of Pathology, 2020, 190, 2226-2236.	1.9	26
90	Regulation of low density lipoprotein metabolism by 26-hydroxycholesterol in human fibroblasts. FEBS Letters, 1987, 218, 77-80.	1.3	25

#	Article	IF	Citations
91	Effects of lacidipine on experimental models of atherosclerosis. Journal of Hypertension, 1993, 11, S61-S66.	0.3	25
92	Statins Effect on Smooth Muscle Cell Proliferation. Seminars in Vascular Medicine, 2004, 4, 347-356.	2.1	25
93	Drugâ€“drug interaction with statins. Expert Review of Clinical Pharmacology, 2008, 1, 105-113.	1.3	24
94	Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 1-9.	3.1	24
95	Synthesis, structural, and biological evaluation of bis-heteroarylmaleimides and bis-heterofused imides. Bioorganic and Medicinal Chemistry, 2011, 19, 5291-5299.	1.4	24
96	Recent advances in synthetic pharmacotherapies for dyslipidaemias. European Journal of Preventive Cardiology, 2020, 27, 1576-1596.	0.8	24
97	Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes. European Journal of Pharmacology, 1998, 355, 77-83.	1.7	23
98	Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. Atherosclerosis, 2003, 166, 395-400.	0.4	23
99	Fluvastatin. Drugs, 2004, 64, 1305-1323.	4.9	23
100	Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. Bioorganic and Medicinal Chemistry, 2008, 16, 1691-1701.	1.4	23
101	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Biochemical and Biophysical Research Communications, 2012, 428, 230-233.	1.0	23
102	Cigarette smoke condensate affects monocyte interaction with endothelium. Atherosclerosis, 2014, 234, 383-390.	0.4	23
103	Familial defective apo B-100, characterization of an Italian family. European Journal of Clinical Investigation, 1991, 21, 389-397.	1.7	22
104	Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clinical Biochemistry, 1992, 25, 399-400.	0.8	22
105	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. Drugs, 2020, 80, 1065-1083.	4.9	22
106	Fluvastatin treatment is not associated with an increased incidence of cancer. International Journal of Clinical Practice, 2006, 60, 1028-1034.	0.8	21
107	Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism. Atherosclerosis, 2011, 215, 70-76.	0.4	21
108	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis, 2015, 114, 186-197.	1.8	21

#	Article	IF	Citations
109	Are pleiotropic effects of statins real?. Vascular Health and Risk Management, 2007, 3, 611-3.	1.0	21
110	Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6192-6196.	1.0	20
111	Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6298-6302.	1.0	20
112	Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5408-5412.	1.0	20
113	Clinical evidence of statin therapy in non-dyslipidemic disorders. Pharmacological Research, 2014, 88, 20-30.	3.1	20
114	Bococizumab for the treatment of hypercholesterolaemia. Expert Opinion on Biological Therapy, 2017, 17, 237-243.	1.4	20
115	Calcium antagonists and low density lipoproteins metabolism by human fibroblasts and by human hepatoma cell line HEP G2. Pharmacological Research Communications, 1986, 18, 1-16.	0.2	19
116	From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. European Journal of Preventive Cardiology, 2018, 25, 1843-1851.	0.8	19
117	[illegible] smooth muscle cell proliferationâ¨2â¨This research was partially supported by Institut of Recherches Internationales Servier, Paris, France. N. Ferri, L. Arnaboldi, and A. Corsini are also partially supported by a grant from the Ministero		

#	Article	IF	Citations
127	Oxidized LDLâ€dependent pathway as new pathogenic trigger in arrhythmogenic cardiomyopathy. EMBO Molecular Medicine, 2021, 13, e14365.	3.3	16
128	Perivascular carotid collar placement induces neointima formation and outward arterial remodeling in mice independent of apolipoprotein E deficiency or Western-type diet feeding. Atherosclerosis, 2007, 195, e112-e124.	0.4	15
129	Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells. Pharmacological Research, 2007, 56, 160-167.	3.1	15
130	Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2924-2927.	1.0	15
131	PCSK9 antagonists and inflammation. Atherosclerosis, 2018, 268, 235-236.	0.4	15
132	Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism. Lipids and Lipid Metabolism, 1991, 1083, 94-100.	2.6	14
133	Raloxifene Elicits Combined Rapid Vasorelaxation and Long-Term Anti-Inflammatory Actions in Rat Aorta. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1444-1451.	1.3	14
134	Global cardiovascular risk management in different Italian regions: An analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. Nutrition, Metabolism and Cardiovascular Diseases, 2012, 22, 635-642.	1.1	14
135	Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2018, 1863, 991-997.	1.2	14
136	Impact of PPAR-Alpha Polymorphismsâ€"The Case of Metabolic Disorders and Atherosclerosis. International Journal of Molecular Sciences, 2019, 20, 4378.	1.8	14
137	In vitro angiogenesis inhibition with selective compounds targeting the key glycolytic enzyme PFKFB3. Pharmacological Research, 2021, 168, 105592.	3.1	14
138	Receptor binding activity of lipid recombinants of apolipoprotein B-100 thrombolytic fragments.. Journal of Lipid Research, 1987, 28, 1410-1423.	2.0	14
139	Statin-Related Muscle Complaints: An Underestimated Risk. Cardiovascular Drugs and Therapy, 2005, 19, 379-381.	1.3	13
140	Isothiazoles. Part XV. A mild andÂefficient synthesis ofÂnew antiproliferative 5-sulfanylsubstituted 3-alkylaminoisothiazole 1,1-dioxides. European Journal of Medicinal Chemistry, 2006, 41, 675-682.	2.6	13
141	Global Cardiovascular Risk Assessment in Different Clinical Settings. High Blood Pressure and Cardiovascular Prevention, 2009, 16, 55-63.	1.0	13
142	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. High Blood Pressure and Cardiovascular Prevention, 2010, 17, 37-47.	1.0	13
143	Lipophilic Î²-adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts. Biochemical Pharmacology, 1987, 36, 1901-1906.	2.0	12
144	Effect of the Nifedipine-Atenolol Association on Arterial Myocyte Migration and Proliferation. Pharmacological Research, 1993, 27, 299-308.	3.1	12

#	Article	IF	Citations
145	New Ras CAAX mimetics: Design, synthesis, antiproliferative activity, and RAS prenylation inhibition. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5500-5504.	1.0	12
146	LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters. Atherosclerosis, 2020, 297, 8-15.	0.4	12
147	27-Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells. FEBS Letters, 1993, 332, 115-118.	1.3	11
148	Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program. Clinical Cardiology, 2011, 34, 560-566.	0.7	11
149	Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. Pharmacological Research, 2017, 122, 96-104.	3.1	11
150	Associations Among PCSK9 Levels, Atherosclerosis-Derived Extracellular Vesicles, and Their miRNA Content in Adults With Obesity. Frontiers in Cardiovascular Medicine, 2021, 8, 785250.	1.1	11
151	Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. Vascular Pharmacology, 2015, 67-69, 38-47.	1.0	10
152	Receptor binding activity of lipid recombinants of apolipoprotein B-100 thrombolytic fragments. Journal of Lipid Research, 1987, 28, 1410-23.	2.0	10
153	Nitric Oxide-Donating Atorvastatin Attenuates Neutrophil Recruitment During Vascular Inflammation Independent of Changes in Plasma Cholesterol. Cardiovascular Drugs and Therapy, 2013, 27, 211-219.	1.3	9
154	Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 334-345.	1.4	9
155	Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies. European Heart Journal Supplements, 2020, 22, E64-E67.	0.0	9
156	The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin. International Journal of Clinical Practice, 2004, 58, 494-503.	0.8	8
157	Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials. European Journal of Internal Medicine, 2010, 21, 372-373.	1.0	8
158	Everolimus in kidney transplant recipients at high cardiovascular risk: a narrative review. Journal of Nephrology, 2020, 33, 69-82.	0.9	8
159	Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?. Current Atherosclerosis Reports, 2022, 24, 161-169.	2.0	8
160	Experimental studies on the hypolipidemic activity of chloridarol. Pharmacological Research Communications, 1983, 15, 201-215.	0.2	7
161	The New Calcium Antagonist Lercanidipine and its Enantiomers Affect Major Processes of AtherogenesisIn Vitro: Is Calcium Entry Involved?. Blood Pressure, 1998, 7, 18-22.	0.7	7
162	Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation. Biochemical Pharmacology, 2005, 70, 1735-1743.	2.0	7

#	Article	IF	Citations
163	An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 19-30.	1.0	7
164	Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitabilityâ€"Evidence from ApoE-/- Mice. International Journal of Molecular Sciences, 2022, 23, 5415.	1.8	7
165	Progesterone modulates the expression of HDL binding sites in human skin fibroblasts. Atherosclerosis, 1988, 74, 107-113.	0.4	6
166	Trapidil derivatives and low density lipoprotein metabolism by human skin fibroblasts and by human hepatoma cell line Hep G2. Pharmacological Research, 1989, 21, 521-531.	3.1	6
167	Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation. Renal Failure, 2005, 27, 259-273.	0.8	6
168	Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion. PLoS ONE, 2013, 8, e71572.	1.1	6
169	Cholesterol Lowering Biotechnological Strategies: From Monoclonal Antibodies to Antisense Therapies. A Pre-Clinical Perspective Review. Cardiovascular Drugs and Therapy, 2023, 37, 585-598.	1.3	6
170	Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Pharmacological Research, 2007, 56, 503-508.	3.1	5
171	Monoclonal antibody 5A binds apolipoprotein B-48 and inhibits the low density lipoprotein-receptor interaction. Biochemical and Biophysical Research Communications, 1989, 162, 908-915.	1.0	4
172	Inhibition of Smooth Muscle Cell Migration and Proliferation by Statins. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2008, 8, 122-140.	0.5	4
173	Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 284-291.	1.0	4
174	PCSK9 Induces Rat Smooth Muscle Cell Proliferation and Counteracts the Pleiotropic Effects of Simvastatin. International Journal of Molecular Sciences, 2021, 22, 4114.	1.8	4
175	Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells. Biology, 2021, 10, 758.	1.3	3
176	Antiatherosclerotic Drugs: A Critical Assessment. Medical Science Symposia Series, 1993, , 317-331.	0.0	3
177	Influence of trapidil and derivatives on cholesterol synthesis and esterification in cultured cells. Pharmacological Research, 1991, 24, 235-242.	3.1	2
178	Effect of atherogenic lipoproteins on PAI-1 synthesis by endothelial cells. Cytotechnology, 1993, 11, S144-S146.	0.7	2
179	Impact of physiciansâ€™ age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme. International Journal of Clinical Practice, 2011, 65, 649-657.	0.8	2
180	The dataset describes: Phenotypic changes induced by cholesterol loading in smooth muscle cells isolated from the aortae of C57BL/6 mice. Data in Brief, 2018, 16, 334-340.	0.5	2

#	Article	IF	Citations
181	Risk Factors for SAMS. Contemporary Cardiology, 2020, , 51-61.	0.0	2
182	History and development of HMG-CoA reductase inhibitors. , 2002, , 1-17.		2
183	Effect of lacidipine, nifedipine, and verapamil on cellular processes of atherogenesis. Pharmacological Research, 1992, 26, 29.	3.1	1
184	Effect of trapidil derivative AR 12456 on intracellular cholesterol homeostasis in human hepatoma cell line Hep G2. Cytotechnology, 1993, 11, S15-S17.	0.7	1
185	Fibrillar Collagen Inhibits Cholesterol Biosynthesis in Human Aortic Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 1631-1637.	1.1	1
186	Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events. Journal of Cardiovascular Medicine, 2017, 18, e91-e93.	0.6	1
187	Multidimensional approach for the proper management of a complex chronic patient with chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 103-112.	1.0	1
188	The Antiatherosclerotic Effect of Calcium Antagonists. Medical Science Symposia Series, 1995, , 103-110.	0.0	1
189	Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. Renal Failure, 2005, 27, 259-73.	0.8	1
190	Results of the Heart Protection Study: can we still assume a class effect?. International Congress Series, 2003, 1253, 253-259.	0.2	0
191	Similarities and Differences between Angiotensin II Type 1 Receptor Antagonists. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 117-121.	1.0	0
192	Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation. Renal Failure, 2005, 27, 259-273.	0.8	0
193	Fluidâ€“Structure Computational Analysis to Investigate the Link between Early Atherogenic Events and the Hemodynamic Environment in an Experimental Model of Intimal Thickening. Cardiovascular Engineering and Technology, 2012, 3, 282-291.	0.7	0
194	Drugâ€“Drug Interaction with DOACs. , 2021, , 41-69.		0
195	Safety of Dyslipidemic Agents. Fundamental and Clinical Cardiology, 2006, , 389-408.	0.0	0
196	Role of Isoprenoids In the Growth-Factor Signal Transduction and their Pharmacological Modulation. Medical Science Symposia Series, 1996, , 103-110.	0.0	0
197	Effect of Statins Beyond Lowering Cholesterol: Where Do We Stand?. Medical Science Symposia Series, 1998, , 253-265.	0.0	0
198	Lipid Lowering Drugs and the Arterial Wall. Medical Science Symposia Series, 1998, , 19-24.	0.0	0